|
1
|
Barr FG, Galili N, Holick J, Biegel JA,
Rovera G and Emanuel BS: Rearrangement of the PAX3 paired box gene
in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat
Genet. 3:113–117. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Collins MH, Zhao H, Womer RB and Barr FG:
Proliferative and apoptotic differences between alveolar
rhabdomyosarcoma subtypes: a comparative study of tumors containing
PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol. 37:83–89.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hazelton BJ, Houghton JA, Parham DM,
Douglass EC, Torrance PM, Holt H and Houghton PJ: Characterization
of cell lines derived from xenografts of childhood
rhabdomyosarcoma. Cancer Res. 47:4501–4507. 1987.PubMed/NCBI
|
|
4
|
Kelly KM, Womer RB and Barr FG: PAX3-FKHR
and PAX7-FKHR gene fusions in rhabdomyosarcoma. J Pediatr Hematol
Oncol. 20:517–518. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sandberg AA, Stone JF, Czarnecki L and
Cohen JD: Hematologic masquerade of rhabdomyosarcoma. Am J Hematol.
68:51–57. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sharp R, Recio JA, Jhappan C, et al:
Synergism between INK4a/ARF inactivation and aberrant HGF/SF
signaling in rhabdomyosarcomagenesis. Nat Med. 8:1276–1280. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gordon T, McManus A, Anderson J, Min T,
Swansbury J, Pritchard-Jones K and Shipley J; United kingdom
Children’s Cancer Study Group; United Kingdom Cancer Cytogenetics
Group. Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United
Kingdom Cancer Cytogenetics Group Study. Med Pediatr Oncol.
36:259–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gurney JG, Severson RK, Davis S and
Robison LL: Incidence of cancer in children in the United States.
Sex-, race-, and 1-year age-specific rates by histologic type.
Cancer. 75:2186–2195. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davis RJ, D’Cruz CM, Lovell MA, Biegel JA
and Barr FG: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14)
translocation in alveolar rhabdomyosarcoma. Cancer Res.
54:2869–2872. 1994.PubMed/NCBI
|
|
10
|
Galili N, Davis RJ, Fredericks WJ,
Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, Rovera G and Barr FG:
Fusion of a fork head domain gene to PAX3 in the solid tumour
alveolar rhabdomyosarcoma. Nat Genet. 5:230–235. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bennicelli JL, Advani S, Schäfer BW and
Barr FG: PAX3 and PAX7 exhibit conserved cis-acting transcription
repression domains and utilize a common gain of function mechanism
in alveolar rhabdomyosarcoma. Oncogene. 18:4348–4356. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barr FG, Nauta LE, Davis RJ, Schäfer BW,
Nycum LM and Biegel JA: In vivo amplification of the PAX3-FKHR and
PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet.
5:15–21. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anderson J, Gordon A, Pritchard-Jones K
and Shipley J: Genes, chromosomes, and rhabdomyosarcoma. Genes
Chromosomes Cancer. 26:275–285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barr FG: Gene fusions involving PAX and
FOX family members in alveolar rhabdomyosarcoma. Oncogene.
20:5736–5746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anderson J, Gordon A, McManus A, Shipley J
and Pritchard-Jones K: Disruption of imprinted genes at chromosome
region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia.
1:340–348. 1999. View Article : Google Scholar
|
|
16
|
Casola S, Pedone PV, Cavazzana AO, Basso
G, Luksch R, d’Amore ES, Carli M, Bruni CB and Riccio A: Expression
and parental imprinting of the H19 gene in human rhabdomyosarcoma.
Oncogene. 14:1503–1510. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhan S, Shapiro DN and Helman LJ:
Activation of an imprinted allele of the insulin-like growth factor
II gene implicated in rhabdomyosarcoma. J Clin Invest. 94:445–448.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schneider G, Bowser MJ, Shin DM, Barr FG
and Ratajczak MZ: The paternally imprinted DLK1-GTL2 locus is
differentially methylated in embryonal and alveolar
rhabdomyosarcomas. Int J Oncol. 44:295–300. 2014.
|
|
19
|
El-Badry OM, Minniti C, Kohn EC, Houghton
PJ, Daughaday WH and Helman LJ: Insulin-like growth factor II acts
as an autocrine growth and motility factor in human
rhabdomyosarcoma tumors. Cell Growth Differ. 1:325–331.
1990.PubMed/NCBI
|
|
20
|
Wang W, Kumar P, Wang W, Epstein J, Helman
L, Moore JV and Kumar S: Insulin-like growth factor II and
PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer
Res. 58:4426–4433. 1998.PubMed/NCBI
|
|
21
|
Hahn H, Wojnowski L, Specht K, et al:
Patched target Igf2 is indispensable for the formation of
medulloblastoma and rhabdomyosarcoma. J Biol Chem. 275:28341–28344.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Makawita S, Ho M, Durbin AD, Thorner PS,
Malkin D and Somers GR: Expression of insulin-like growth factor
pathway proteins in rhabdomyosarcoma: IGF-2 expression is
associated with translocation-negative tumors. Pediatr Dev Pathol.
12:127–135. 2009. View Article : Google Scholar
|
|
23
|
Rikhof B, de Jong S, Suurmeijer AJ, Meijer
C and van der Graaf WT: The insulin-like growth factor system and
sarcomas. J Pathol. 217:469–482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martins AS, Olmos D, Missiaglia E and
Shipley J: Targeting the insulin-like growth factor pathway in
rhabdomyosarcomas: rationale and future perspectives. Sarcoma.
2011:2097362011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gallagher EJ and LeRoith D: The
proliferating role of insulin and insulin-like growth factors in
cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshimizu T, Miroglio A, Ripoche MA, et
al: The H19 locus acts in vivo as a tumor suppressor. Proc Natl
Acad Sci USA. 105:12417–12422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lottin S, Adriaenssens E, Dupressoir T,
Berteaux N, Montpellier C, Coll J, Dugimont T and Curgy JJ:
Overexpression of an ectopic H19 gene enhances the tumorigenic
properties of breast cancer cells. Carcinogenesis. 23:1885–1895.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Keniry A, Oxley D, Monnier P, Kyba M,
Dandolo L, Smits G and Reik W: The H19 lincRNA is a developmental
reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell
Biol. 14:659–665. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kimura S, Kuramoto K, Homan J, Naruoka H,
Ego T, Nogawa M, Sugahara S and Naito H: Antiproliferative and
antitumor effects of azacitidine against the human myelodysplastic
syndrome cell line SKM-1. Anticancer Res. 32:795–798.
2012.PubMed/NCBI
|
|
30
|
Thakur S, Feng X, Qiao Shi Z, Ganapathy A,
Kumar Mishra M, Atadja P, Morris D and Riabowol K: ING1 and
5-azacytidine act synergistically to block breast cancer cell
growth. PLoS One. 7:e436712012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grymula K, Tarnowski M, Wysoczynski M,
Drukala J, Barr FG, Ratajczak J, Kucia M and Ratajczak MZ:
Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1
axes in regulating metastatic behavior of human rhabdomyosarcomas.
Int J Cancer. 127:2554–2568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kerjean A, Dupont JM, Vasseur C, Le
Tessier D, Cuisset L, Pàldi A, Jouannet P and Jeanpierre M:
Establishment of the paternal methylation imprint of the human H19
and MEST/PEG1 genes during spermatogenesis. Hum Mol Genet.
9:2183–2187. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tarnowski M, Schneider G, Amann G, Clark
G, Houghton P, Barr FG, Kenner L, Ratajczak MZ and Kucia M: RasGRF1
regulates proliferation and metastatic behavior of human alveolar
rhabdomyosarcomas. Int J Oncol. 41:995–1004. 2012.PubMed/NCBI
|
|
34
|
Baylin SB, Herman JG, Graff JR, Vertino PM
and Issa JP: Alterations in DNA methylation: a fundamental aspect
of neoplasia. Adv Cancer Res. 72:141–196. 1998. View Article : Google Scholar
|
|
35
|
Bird A: The essentials of DNA methylation.
Cell. 70:5–8. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leonhardt H and Cardoso MC: DNA
methylation, nuclear structure, gene expression and cancer. J Cell
Biochem. (Suppl 35): 78–83. 2000. View Article : Google Scholar
|
|
37
|
Esteller M: Cancer epigenetics: DNA
methylation and chromatin alterations in human cancer. Adv Exp Med
Biol. 532:39–49. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dammann RH, Kirsch S, Schagdarsurengin U,
Dansranjavin T, Gradhand E, Schmitt WD and Hauptmann S: Frequent
aberrant methylation of the imprinted IGF2/H19 locus and LINE1
hypomethylation in ovarian carcinoma. Int J Oncol. 36:171–179.
2010.
|
|
39
|
Smilinich NJ, Day CD, Fitzpatrick GV, et
al: A maternally methylated CpG island in KvLQT1 is associated with
an antisense paternal transcript and loss of imprinting in
Beckwith-Wiedemann syndrome. Proc Natl Acad Sci USA. 96:8064–8069.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bell AC and Felsenfeld G: Methylation of a
CTCF-dependent boundary controls imprinted expression of the Igf2
gene. Nature. 405:482–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feinberg AP: Phenotypic plasticity and the
epigenetics of human disease. Nature. 447:433–440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feinberg AP: The two-domain hypothesis in
Beckwith-Wiedemann syndrome. J Clin Invest. 106:739–740. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lynch CA, Tycko B, Bestor TH and Walsh CP:
Reactivation of a silenced H19 gene in human rhabdomyosarcoma by
demethylation of DNA but not by histone hyperacetylation. Mol
Cancer. 1:22002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grandjean V, O’Neill L, Sado T, Turner B
and Ferguson-Smith A: Relationship between DNA methylation, histone
H4 acetylation and gene expression in the mouse imprinted Igf2-H19
domain. FEBS Lett. 488:165–169. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Svensson K, Mattsson R, James TC, Wentzel
P, Pilartz M, MacLaughlin J, Miller SJ, Olsson T, Eriksson UJ and
Ohlsson R: The paternal allele of the H19 gene is progressively
silenced during early mouse development: the acetylation status of
histones may be involved in the generation of variegated expression
patterns. Development. 125:61–69. 1998.
|
|
46
|
Jones PA, Taylor SM and Wilson VL:
Inhibition of DNA methylation by 5-azacytidine. Recent Results
Cancer Res. 84:202–211. 1983.PubMed/NCBI
|
|
47
|
Taylor SM and Jones PA: Mechanism of
action of eukaryotic DNA methyltransferase. Use of
5-azacytosine-containing DNA. J Mol Biol. 162:679–692. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hollenbach PW, Nguyen AN, Brady H,
Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C and
MacBeth KJ: A comparison of azacitidine and decitabine activities
in acute myeloid leukemia cell lines. PLoS One. 5:e90012010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Greggs WM 3rd, Clouser CL, Patterson SE
and Mansky LM: Discovery of drugs that possess activity against
feline leukemia virus. J Gen Virol. 93:900–905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dapp MJ, Clouser CL, Patterson S and
Mansky LM: 5-Azacytidine can induce lethal mutagenesis in human
immunodeficiency virus type 1. J Virol. 83:11950–11958. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Clouser CL, Patterson SE and Mansky LM:
Exploiting drug repositioning for discovery of a novel HIV
combination therapy. J Virol. 84:9301–9309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ley TJ, DeSimone J, Anagnou NP, Keller GH,
Humphries RK, Turner PH, Young NS, Keller P and Nienhuis AW:
5-Azacytidine selectively increases gamma-globin synthesis in a
patient with beta+ thalassemia. N Engl J Med. 307:1469–1475. 1982.
View Article : Google Scholar : PubMed/NCBI
|
